Global Porphyrias Treatments Market Size To Exceed USD 3.01 Billion By 2035 | CAGR of 9.14%
Category: HealthcareGlobal Porphyrias Treatments Market Size to Exceed $ 3.01 Billion by 2035
According to a research report published by Spherical Insights & Consulting, The Global Porphyrias Treatments Market Size is expected to grow from USD 1.15 billion in 2024 to USD 3.01 billion by 2035, at a CAGR of 9.14% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 201 pages with 119 Market data tables and figures & charts from the report on the "Global Porphyrias Treatments Market Size, Share, and COVID-19 Impact Analysis, By Treatment Types (Porphyrin, Dextrose, Anticonvulsants, Opioids, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/porphyrias-treatments-market
The porphyrias treatments market refers to the industry emphasizing the management of symptoms and complications associated with porphyria, which is a group of rare genetic disorders. Porphyrias are characterized by the substances called porphyrins that build up in the body, adversely affecting the skin or nervous system. Depending on the type of porphyria and the person’s symptoms, the treatment generally involves the avoidance of sunlight in case of skin porphyria, while giving intravenous heme or a glucose solution in case of acute porphyria. Ongoing progress in nanotechnology and nanoscience for targeting disease, especially hepatic and erythropoietic related diseases, along with an increasing initiatives and R&D activities, are bolstering the market growth opportunity. Increasing advancements and research on congenital erythropoietic porphyria are driving the market growth of porphyria treatments. With an increasing porphyrias awareness, emphasis on research, development, and commercialization of novel treatments is driving the market. On the contrary, increased treatment costs, limited diagnosis, and intense competition are challenging the porphyria treatments market.
The porphyrin segment dominated the market with the largest share of about 40% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the treatment types, the porphyrias treatments market is divided into porphyrin, dextrose, anticonvulsants, opioids, and others. Among these, the porphyrin segment dominated the market with the largest share of about 40% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Hemin, which is iron iron-containing porphyrin prescribed for certain blood disorders (porphyria) related symptoms. The increasing prevalence of porphyria diseases and the increase in the number of diagnostic laboratories are contributing to propel the market demand in the porphyrin segment.
The hospital pharmacies segment accounted for the largest revenue share of about 50% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the distribution channel, the porphyrias treatments market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the largest revenue share of about 50% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. For instance, Panhematin is a commercially available heme therapy in the United States recommended only after several days of glucose therapy have been unsuccessful. The ease of accessibility, along with an increased number of hospital admissions, is propelling the market growth.
North America is expected to hold the majority share of the global Porphyrias Treatments market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 45% in the global porphyrias treatments market during the forecast period. The U.S. is leading the North America porphyrias treatments market, accounting for about 45% revenue share in the region, owing to the improved diagnostics like genetic testing and new targeted therapies, especially for acute hepatic porphyria. The emergence of cutting-edge therapies and novel strategies for acute intermittent porphyria is driving the market growth. Companies are increasingly implementing programs for introducing the novel drugs, which is promoting the market growth.
Asia Pacific is anticipated to grow at the fastest pace of about 9.5% CAGR in the global porphyrias treatments market during the forecast period. Japan is anticipated to dominate the Asia Pacific porphyrias treatments market, with a significant market share, driven by ongoing research for optimising clinical findings of therapeutic medicine. The region’s large population base, government initiatives, and growth of healthcare infrastructure are responsible for driving the porphyrias treatments market.
Major vendors in the global Porphyrias Treatments market are ACON Laboratories, Inc., Bio-Rad Laboratories, Inc., Dahaner, Hoffmann-La Roche Ltd., Siemens AG, ARKRAY, Inc., Sysmex Corporation, Lundbeck, Recordati Rare Diseases, Teva Pharmaceutical, Apotex, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In September 2025, Disc Medicine, Inc., a clinical-stage biopharmaceutical company, announced the submission for a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Porphyrias Treatments market based on the below-mentioned segments:
Global Porphyrias Treatments Market, By Treatment Types
- Porphyrin
- Dextrose
- Anticonvulsants
- Opioids
- Others
Global Porphyrias Treatments Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Porphyrias Treatments Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?